Fig. 6

Modulation of downstream targets of FLT3 activation by Gilteritinib plus ATO treatment in MOLM13 cells. a–f MOLM13 cells were treated with Gilteritinib (2.5 nM) and/or ATO (0.5 µM) for 48 h and protein levels of P-STAT5, STAT5, P-AKT, AKT, P-ERK and ERK were determined by western blot. DMSO treated cells served as a control. Data are shown as mean ± SD for three separate experiments, ***P < 0.001. P-STAT5 phosphorylated-STAT5, P-AKT phosphorylated-AKT, P-ERK phosphorylated-ERK